CHRISTOF WESTENFELDER, MD
Osteopathic Medicine at Medical Dr, Salt Lake City, UT
License number
Utah 169683-1205
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
50 N Medical Dr, Salt Lake City, UT 84132
Phone
(801) 581-6709
(801) 213-3800
(801) 213-3800
Personal information
See more information about CHRISTOF WESTENFELDER at radaris.comName
Address
Phone
702 Cortez St, Salt Lake Cty, UT 84103
702 Cortez St, Salt Lake City, UT 84103
Organization information
See more information about CHRISTOF WESTENFELDER at bizstanding.comChristof Westenfelder MD
50 N Medical Dr, Salt Lake City, UT 84132
Industry:
Internist
Phone:
(801) 581-6709 (Phone)
Christof Westenfelder
Professional information
See more information about CHRISTOF WESTENFELDER at trustoria.com
Profgessor Of Medicine And Physiology At University Of Utah
Profgessor Of Medicine And Physiology At University Of Utah
Position:
Profgessor of Medicine and Physiology at University of Utah
Location:
Greater Salt Lake City Area
Industry:
Hospital & Health Care
Work:
University of Utah
-
Profgessor of Medicine and Physiology
Christof Westenfelder, Salt Lake City UT
Christof Westenfelder, Salt Lake City UT
Specialties:
Internal Medicine, Nephrology
Work:
Uumc Nephrology
50 N Medical Dr, Salt Lake City, UT 84132 VA Med Ctr-127
500 Foothill Dr, Salt Lake City, UT 84148
50 N Medical Dr, Salt Lake City, UT 84132 VA Med Ctr-127
500 Foothill Dr, Salt Lake City, UT 84148
Education:
Med Acad Luebeck 2nd Fac Med Christian Albrechts Univ, Kiel, Luebeck (1968)
Therapy Of Kidney Diseases And Multiorgan Failure With Mesenchymal Stem Cells And Mesenchymal Stem Cell Conditioned Media
Therapy Of Kidney Diseases And Multiorgan Failure With Mesenchymal Stem Cells And Mesenchymal Stem Cell Conditioned Media
US Patent:
2008024, Oct 2, 2008
Filed:
May 10, 2005
Appl. No.:
11/913900
Inventors:
Christof Westenfelder - Salt Lake City UT, US
International Classification:
A61K 35/12, A61P 13/12, A61P 17/02, A61P 29/00
US Classification:
424 937
Abstract:
Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided.
Mesenchymal Stromal Cell Populations And Methods Of Using Same
Mesenchymal Stromal Cell Populations And Methods Of Using Same
US Patent:
2012026, Oct 25, 2012
Filed:
Oct 29, 2010
Appl. No.:
13/504070
Inventors:
Christof Westenfelder - Salt Lake City UT, US
Assignee:
ALLOCURE, INC. - Burlington MA
International Classification:
A61K 35/28, A61P 13/12
US Classification:
424 937
Abstract:
The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders.
Marrow Stem Cell And Pancreatic Beta Cell Fusion Cell Useful For The Treatment Of Diabetes
Marrow Stem Cell And Pancreatic Beta Cell Fusion Cell Useful For The Treatment Of Diabetes
US Patent:
8119120, Feb 21, 2012
Filed:
Sep 19, 2007
Appl. No.:
12/311090
Inventors:
Christof Westenfelder - Salt Lake City UT, US
Assignee:
Insugen, LLC - Salt Lake City UT
International Classification:
C12N 15/00
US Classification:
424 932, 435346, 435449
Abstract:
Methods disclosed include methods of treating T1DM, said method comprising delivering a therapeutic amount of β-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell.
Assay For The Prediction Of Therapeutic Effectiveness Of Mesenchymal Stromal Cells, And Methods Of Using Same
Assay For The Prediction Of Therapeutic Effectiveness Of Mesenchymal Stromal Cells, And Methods Of Using Same
US Patent:
2012027, Nov 1, 2012
Filed:
Oct 13, 2010
Appl. No.:
13/501230
Inventors:
Christof Westenfelder - Salt Lake City UT, US
Assignee:
Allocure, Inc. - Burlington MA
International Classification:
A61K 35/12, G01N 33/566, A61P 3/10, A61P 25/00, C12Q 1/68, A61P 29/00
US Classification:
424 937, 435 612, 435 792
Abstract:
The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations.
Marrow Stem Cell And Pancreatic Β Cell Fusion Cell Useful For The Treatment Of Diabetes
Marrow Stem Cell And Pancreatic Β Cell Fusion Cell Useful For The Treatment Of Diabetes
US Patent:
8372641, Feb 12, 2013
Filed:
Feb 17, 2012
Appl. No.:
13/399750
Inventors:
Christof Westenfelder - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
U.S. Department of Veteran Affairs - Washington DC
U.S. Department of Veteran Affairs - Washington DC
International Classification:
C12N 5/00, A61K 38/00
US Classification:
435366, 435325, 424 932
Abstract:
Methods described include methods of treating T1DM, the method comprising delivering a therapeutic amount of β-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell.
Stem-Cell, Precursor Cell, Or Target Cell-Based Treatment Of Multi-Organ Failure And Renal Dysfunction
Stem-Cell, Precursor Cell, Or Target Cell-Based Treatment Of Multi-Organ Failure And Renal Dysfunction
US Patent:
8603462, Dec 10, 2013
Filed:
Mar 31, 2004
Appl. No.:
10/551317
Inventors:
Christof Westenfelder - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
United States of America Department of Veteran's Affairs. - Washington DC
United States of America Department of Veteran's Affairs. - Washington DC
International Classification:
A01N 63/00, C12N 5/0775
US Classification:
424 937, 424 9321, 435372
Abstract:
Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.
Method Of Use Of Erythropoietin To Treat Ischemic Acute Renal Failure
Method Of Use Of Erythropoietin To Treat Ischemic Acute Renal Failure
US Patent:
2003008, May 1, 2003
Filed:
Nov 1, 2001
Appl. No.:
10/003352
Inventors:
Christof Westenfelder - Salt Lake City UT, US
Assignee:
University of Utah
International Classification:
A61K038/22
US Classification:
514/012000
Abstract:
Recombinant erythropoietin is used in a method to prevent ischemic acute renal failure in patients at risk for developing ischemic acute renal failure and to treat fully-developed ischemic acute renal failure. The method is also used to prevent harmful cell apoptosis in renal tubular cells and to stimulate mitogenesis and motogenesis in renal tubular cells. The method comprises the administration of a composition of recombinant erythropoietin in a pharmacologically acceptable carrier to a patient for the purpose of preventing the development of ischemic acute renal failure, treating established acute renal failure, preventing harmful cell apoptosis in renal tubular cells.
Potentiation Of Stem Cell Homing And Treatment Of Organ Dysfunction Or Organ Failure
Potentiation Of Stem Cell Homing And Treatment Of Organ Dysfunction Or Organ Failure
US Patent:
2010024, Sep 30, 2010
Filed:
Feb 1, 2008
Appl. No.:
12/525592
Inventors:
Christof Westenfelder - Salt Lake City UT, US
International Classification:
A61K 35/12, A61P 13/12
US Classification:
424 937
Abstract:
The invention provides methods and compositions for the treatment of multi-organ failure or kidney dysfunction, such as acute renal failure, by mesenchymal stem cells and a CD26 inhibitor, where inhibition of CD26 increases homing of the mesenchymal stem cells to a target tissue.